VolitionRX Limited Intellectual Property Update: New Patent Filed

SINGAPORE, Dec. 22, 2011 /PRNewswire/ -- VolitionRX Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, is pleased to announce that it has filed a further patent application building on its Nucleosomics technology platform.

VolitionRX has developed methods to detect nucleosome adducts of cancer origin which are circulating in the blood of cancer patients and has filed a patent application covering both the use of these adducts as biomarkers and the methods for their detection. The new patent application, "Method For Detecting Nucleosome Adducts" [US 61/568,090] was filed on December 7, 2011. The existence of these nucleosome adducts was previously unknown.

Jake Micallef, Chief Scientific Officer of Belgian Volition says, "We have high hopes that these advances will find application in the diagnosis of certain cancers, particularly cancers whose growth is steroid dependent."

Cameron Reynolds, CEO of VolitionRX says, "Our scientific team is carrying out work on two Nucleosomics fronts at present: continuing internal validations of our technology on blood samples from cancer and non-cancer patients; and finding other novel applications for Nucleosomics. We are very excited that our team has discovered another promising potential diagnostic application from our Nucleosomics patent estate."

About VolitionRX

VolitionRX is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats.

VolitionRX is managed by a well-respected team with extensive experience in diagnostics and commercialization. VolitionRX's development activities are currently centered in Belgium and will be augmented by commercialization work in Singapore with a focus on bringing its revolutionary diagnostic products to market first in Europe, then the U.S. and worldwide.

VolitionRX is quoted on the OTC Bulletin Board in the United States of America, under the symbol VNRX.OB.

Forward-Looking Statements: Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.

SOURCE VolitionRX Limited